サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413450

強皮症診断・治療市場：診断テスト、薬剤タイプ、治療、適応症別 - 2024年～2030年の世界予測

Scleroderma Diagnostics & Therapeutics Market by Diagnostic Tests (Blood Tests, Imaging, Pulmonary Function Tests), Drug Type (Calcium Channel Blockers, Chelating Agents, Corticosteroids), Therapeutics, Indication - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
強皮症診断・治療市場：診断テスト、薬剤タイプ、治療、適応症別 - 2024年～2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

強皮症診断・治療市場規模は2023年に20億9,000万米ドルと推計され、2024年には21億9,000万米ドルに達し、CAGR 6.25%で2030年には32億米ドルに達すると予測されます。

強皮症診断・治療の世界市場

主な市場の統計
基準年[2023年］ 20億9,000万米ドル
予測年[2024年］ 21億9,000万米ドル
予測年 [2030年] 32億米ドル
CAGR（%） 6.25%
Scleroderma Diagnostics &Therapeutics Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは強皮症診断・治療市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、強皮症診断・治療市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-強皮症診断・治療市場の市場規模および予測は？

2-強皮症診断・治療市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-強皮症診断・治療市場における技術動向と規制の枠組みは？

4-強皮症診断・治療市場における主要ベンダーの市場シェアは？

5-強皮症診断・治療市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 強皮症の有病率の増加と効果的な診断技術と治療の必要性
      • 強皮症の状態に対する意識の高まりと早期診断の重視
      • 新しい薬や治療法の開発のための臨床試験の数が増加
    • 抑制要因
      • 強皮症の治療に伴う高額な費用
    • 機会
      • 画像技術やバイオマーカーの同定などの診断技術の進歩
      • 強皮症の効果的な治療選択肢を特定するための継続的な調査
    • 課題
      • 強皮症の治療に使用される薬剤に関連する副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 強皮症診断・治療市場：診断テスト別

  • 血液検査
  • イメージング
    • CTスキャン
    • MRI
    • X線
  • 肺機能検査
  • 皮膚生検

第7章 強皮症診断・治療市場：薬剤タイプ別

  • カルシウムチャネルブロッカー
  • キレート剤
  • コルチコステロイド
  • エンドセリン受容体アゴニスト
  • 免疫抑制剤
  • PDE-5阻害剤
  • プロスタサイクリン類似体

第8章 強皮症診断・治療市場：治療別

  • 生物学的療法
  • 遺伝子治療
  • 肺線維症の治療
  • レイノー現象の管理
  • 幹細胞移植

第9章 強皮症診断・治療市場：適応症別

  • 局所性
  • 全身性

第10章 南北アメリカの強皮症診断・治療市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の強皮症診断・治療市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの強皮症診断・治療市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • Antibodies Inc.
    • AstraZeneca plc
    • Bayer AG
    • Bio-Rad Laboratories, Inc
    • Biogen Inc.
    • Boehringer Ingelheim Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd.
    • Galapagos NV
    • Gilead Sciences, Inc.
    • GlaxoSmithKline plc（GSK）
    • Merck & Co., Inc.
    • Myriad Genetics, Inc
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi Genzyme
    • Takeda Pharmaceutical Company Limited
    • The Bristol-Myers Squibb Company
    • Thermo Fisher Scientific Inc.
    • Trinity Biotech plc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 8. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 10. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 12. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 14. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 6. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 9. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CT SCANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY X-RAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SKIN BIOPSIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHELATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ENDOTHELIN RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PDE-5 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PROSTACYCLIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 23. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PULMONARY FIBROSIS TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY RAYNAUD'S PHENOMENON MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY LOCALIZED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 240. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. SCLERODERMA DIAGNOSTICS & THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-8E22B61932E7

[186 Pages Report] The Scleroderma Diagnostics & Therapeutics Market size was estimated at USD 2.09 billion in 2023 and expected to reach USD 2.19 billion in 2024, at a CAGR 6.25% to reach USD 3.20 billion by 2030.

Global Scleroderma Diagnostics & Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.09 billion
Estimated Year [2024] USD 2.19 billion
Forecast Year [2030] USD 3.20 billion
CAGR (%) 6.25%
Scleroderma Diagnostics & Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Scleroderma Diagnostics & Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Scleroderma Diagnostics & Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Scleroderma Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Antibodies Inc., AstraZeneca plc, Bayer AG, Bio-Rad Laboratories, Inc, Biogen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd., Galapagos NV, Gilead Sciences, Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc., Myriad Genetics, Inc, Novartis AG, PerkinElmer Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Takeda Pharmaceutical Company Limited, The Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., and Trinity Biotech plc..

Market Segmentation & Coverage

This research report categorizes the Scleroderma Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Tests
    • Blood Tests
    • Imaging
      • CT Scans
      • MRI
      • X-rays
    • Pulmonary Function Tests
    • Skin Biopsies
  • Drug Type
    • Calcium Channel Blockers
    • Chelating Agents
    • Corticosteroids
    • Endothelin Receptor Agonists
    • Immunosuppressive Agents
    • PDE-5 Inhibitors
    • Prostacyclin Analogues
  • Therapeutics
    • Biologic Therapies
    • Gene Therapy
    • Pulmonary Fibrosis Treatments
    • Raynaud's Phenomenon Management
    • Stem Cell Transplantation
  • Indication
    • Localized
    • Systemic
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Scleroderma Diagnostics & Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Scleroderma Diagnostics & Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Scleroderma Diagnostics & Therapeutics Market?

4. What is the market share of the leading vendors in the Scleroderma Diagnostics & Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Scleroderma Diagnostics & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Scleroderma Diagnostics & Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of scleroderma and the need for effective diagnostic techniques and therapies
      • 5.1.1.2. Growing awareness about scleroderma condition and emphasis on early diagnosis
      • 5.1.1.3. Rising number of clinical trials for the development of novel drugs and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with scleroderma treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in diagnostic technologies, such as imaging techniques and biomarker identification
      • 5.1.3.2. Ongoing research for identifying efficient treatment options for scleroderma
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with the drugs used in scleroderma treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Scleroderma Diagnostics & Therapeutics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Blood Tests
  • 6.3. Imaging
    • 6.4.1. CT Scans
    • 6.4.2. MRI
    • 6.4.3. X-rays
  • 6.4. Pulmonary Function Tests
  • 6.5. Skin Biopsies

7. Scleroderma Diagnostics & Therapeutics Market, by Drug Type

  • 7.1. Introduction
  • 7.2. Calcium Channel Blockers
  • 7.3. Chelating Agents
  • 7.4. Corticosteroids
  • 7.5. Endothelin Receptor Agonists
  • 7.6. Immunosuppressive Agents
  • 7.7. PDE-5 Inhibitors
  • 7.8. Prostacyclin Analogues

8. Scleroderma Diagnostics & Therapeutics Market, by Therapeutics

  • 8.1. Introduction
  • 8.2. Biologic Therapies
  • 8.3. Gene Therapy
  • 8.4. Pulmonary Fibrosis Treatments
  • 8.5. Raynaud's Phenomenon Management
  • 8.6. Stem Cell Transplantation

9. Scleroderma Diagnostics & Therapeutics Market, by Indication

  • 9.1. Introduction
  • 9.2. Localized
  • 9.3. Systemic

10. Americas Scleroderma Diagnostics & Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Scleroderma Diagnostics & Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Scleroderma Diagnostics & Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. AbbVie Inc.
    • 14.1.2. Amgen Inc.
    • 14.1.3. Antibodies Inc.
    • 14.1.4. AstraZeneca plc
    • 14.1.5. Bayer AG
    • 14.1.6. Bio-Rad Laboratories, Inc
    • 14.1.7. Biogen Inc.
    • 14.1.8. Boehringer Ingelheim Pharmaceuticals, Inc.
    • 14.1.9. Eli Lilly and Company
    • 14.1.10. Exagen Inc.
    • 14.1.11. F. Hoffmann-La Roche Ltd.
    • 14.1.12. Galapagos NV
    • 14.1.13. Gilead Sciences, Inc.
    • 14.1.14. GlaxoSmithKline plc (GSK)
    • 14.1.15. Merck & Co., Inc.
    • 14.1.16. Myriad Genetics, Inc
    • 14.1.17. Novartis AG
    • 14.1.18. PerkinElmer Inc.
    • 14.1.19. Pfizer Inc.
    • 14.1.20. Regeneron Pharmaceuticals, Inc.
    • 14.1.21. Sanofi Genzyme
    • 14.1.22. Takeda Pharmaceutical Company Limited
    • 14.1.23. The Bristol-Myers Squibb Company
    • 14.1.24. Thermo Fisher Scientific Inc.
    • 14.1.25. Trinity Biotech plc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing